TGTX Key Statistics, Chart & Performance
The current stock price of TGTX is 33.41 USD. In the past month the price decreased by -1.1%. In the past year, price decreased by -3.99%.
TGTX Latest News, Press Relases and Analysis
TGTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.09 | 402.18B | ||
| AMGN | AMGEN INC | 15.76 | 185.50B | ||
| GILD | GILEAD SCIENCES INC | 15.57 | 158.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.89 | 110.80B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.43 | 83.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 872.78 | 58.35B | ||
| INSM | INSMED INC | N/A | 43.23B | ||
| NTRA | NATERA INC | N/A | 32.54B | ||
| BIIB | BIOGEN INC | 10.87 | 26.67B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.51 | 22.09B | ||
| INCY | INCYTE CORP | 16.46 | 20.63B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.21B |
Related stock screener links
About TGTX
Company Profile
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in Morrisville, North Carolina and currently employs 370 full-time employees. The firm is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. The company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
Company Info
TG THERAPEUTICS INC
3020 Carrington Mill Blvd., Suite 475
Morrisville NORTH CAROLINA 10014 US
CEO: Michael S. Weiss
Employees: 370
Phone: 18775758489
TG THERAPEUTICS INC / TGTX FAQ
What does TGTX do?
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in Morrisville, North Carolina and currently employs 370 full-time employees. The firm is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. The company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
Can you provide the latest stock price for TG THERAPEUTICS INC?
The current stock price of TGTX is 33.41 USD. The price increased by 1.3% in the last trading session.
What is the dividend status of TG THERAPEUTICS INC?
TGTX does not pay a dividend.
What is the ChartMill rating of TG THERAPEUTICS INC stock?
TGTX has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the GICS sector and industry of TGTX stock?
TG THERAPEUTICS INC (TGTX) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of TGTX stock?
TG THERAPEUTICS INC (TGTX) has a market capitalization of 5.30B USD. This makes TGTX a Mid Cap stock.
TGTX Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to TGTX. When comparing the yearly performance of all stocks, TGTX turns out to be only a medium performer in the overall market: it outperformed 63.53% of all stocks.
TGTX Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to TGTX. Both the profitability and the financial health of TGTX get a neutral evaluation. Nothing too spectacular is happening here.
TGTX Financial Highlights
Over the last trailing twelve months TGTX reported a non-GAAP Earnings per Share(EPS) of 0.51. The EPS increased by 563.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 84.13% | ||
| ROA | 43.65% | ||
| ROE | 73.69% | ||
| Debt/Equity | 0.4 |
TGTX Forecast & Estimates
15 analysts have analysed TGTX and the average price target is 45.17 USD. This implies a price increase of 35.2% is expected in the next year compared to the current price of 33.41.
For the next year, analysts expect an EPS growth of 450.98% and a revenue growth 83.64% for TGTX